Aminolevulinic acid hydrochloride is under clinical development by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical and currently in Phase II for Human Papillomavirus Infections. According to GlobalData, Phase II drugs for Human Papillomavirus Infections have a 19% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aminolevulinic acid hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aminolevulinic acid hydrochloride overview
Aminolevulinic acid hydrochloride (ALA) is a second generation photodynamic drug. It is formulated as powder for topical route of administration. It is used to treatment for CA traditional areas, fill a gap in urethral orifice CA cure, become the best treatment for CA in preferred therapy.
See Also:
It is under development for the treatment of cervical intraepithelial neoplasia infected by human papilloma virus (HPV), actinic keratosis, acne and breast cancer. It was also under development for basal cell carcinoma and as adjuvant therapy for the treatment brain gliomas.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical overview
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (FDZJ), a subsidiary of Shanghai Pharmaceutical Co Ltd, develops, manufactures and markets genetic engineering drugs. It primarily develops nanotechnology drugs, photodynamic technology drugs, genetic engineering technology drugs and oral solid preparation technology drugs. The company’s major products include ALA (aminolevulinic acid hydrochloride), hemoprotein for injection and doxorubicin liposome and doxorubicin hydrochloride liposome injection, among others. FDZJ is headquartered in Shanghai, China.
For a complete picture of Aminolevulinic acid hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
